FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
|
|
- Damon Wilkins
- 5 years ago
- Views:
Transcription
1 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009
2 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A) (B) (A)-(B) (C) (A)-(C) Net sales Operating income (Ratio) 6.9 (1.2%) 10.4 (1.6%) (3.7%) Ordinary income (Ratio) 12.6 (2.2%) 8.2 (1.2%) (5.0%) Net income (Ratio) 2.1 (0.4%) 5.8 (0.9%) (2.9%) -23.9
3 Consolidated: Net Sales Page 3 Domestic production Domestic sales Domestic production Overseas sales Overseas production Overseas sales FY2008 1Q (08/4-6) FY2008 4Q (09/1-3) FY2009 1Q (09/4-6)
4 Motorcycle Automobile Marine & Power products, etc. Total Page 4 Influence of exchange fluctuations included Domestic total Overseas total Europe North America Asia Others Total Influence of exchange fluctuations included Consolidated: Net Sales (Year-to-Year Comparison) Excluding Financial Services business
5 Consolidated: Operating Income Page Decreased by 26.9 billion (-79.7%) y-o-y Profit ratio 3.7% 10.4 Profit ratio 1.6% 6.9 Profit ratio 1.2% FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
6 Consolidated: Ordinary Income Page 6 Decreased by 32.8 billion (-72.3%) y-o-y 45.4 Profit ratio 5.0% 8.2 Profit ratio 1.2% 12.6 Profit ratio 2.2% FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
7 Consolidated: Net Income Page 7 Decreased by 23.9 billion (-91.8%) y-o-y 26.0 Profit ratio 2.9% 5.8 Profit ratio 0.9% 2.1 Profit ratio 0.4% FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
8 Consolidated: Factors of Change in Operating Income Page Decrease of Cost reduction Decrease of R&D expenses Decrease of operatin g expenses, etc depreciation +9.0 Change in sales, model mix, etc FY2008 1Q Operating income 33.8 Factor of increase (+68.2) Operating income decrease (-26.9) Factor of decrease (-95.1) Fore ign exchange loss FY2009 1Q Operating income 6.9 (Change in sales, model mix, etc. includes influence of raw material +5.1)
9 Consolidated: Foreign Exchange Rates Page 9 FY2009 1Q (09/4-6) FY2008 1Q (08/4-6) U.S. dollar Euro Others 97 yen 135 yen ー 110 yen 161 yen ー Change -13 yen -26 yen ー ForEX loss -2.7 bln yen -6.0 bln yen bln yen Total bln yen
10 Consolidated: Capital Expenditures (including amount of main affiliates) Page 10 SUZUKI Subsidiaries Main affiliates FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
11 Consolidated: Depreciation, R&D Expenses, Interest-Bearing Debt Page Financial Services 92.5 included Depreciation R&D expenses Interest-bearing debt FY2008 1Q FY2009 1Q FY2008 1Q FY2009 1Q (08/4-6) (09/4-6) (08/4-6) (09/4-6) FY2008 1Q FY2009 1Q (08/6) (09/6)
12 Consolidated:Cash Flows Page 12 Operating activities Investment activities Financing activities Others +4.0 At beginning of FY Free cash flow 29.5 Cash and cash equivalents Increased by 65.4 At end of FY2009 1Q 493.2
13 Consolidated:Cash Flows Page 13 09/4~6 09/1~3 Change 08/4~6 Change (Billion Yen) (A) (B) (A)-(B) (C) (A)-(C) Operating activities Investment activities Free cash flow Financing activities Others Total amount of change
14 Consolidated: Business Segment Page Net sales Financial Services Marine & Power products, etc. Motorcycle Automobile Operating income Motorcycle Financial Services FY2008 1Q FY2008 4Q FY2009 1Q FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6) (08/4-6) (09/1-3) (09/4-6)
15 159.8 Consolidated: Business Segment - Motorcycle Page 15 Net sales Operating income ー FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
16 Consolidated: Business Segment - Automobile Page Net sales Operating income FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
17 Consolidated: Business Segment - Marine and Power products, etc. Page Net sales Operating income FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
18 Consolidated: Geographical Segment Page Net sales Others Asia North America Europe Japan Operating income FY2008 1Q FY2008 4Q FY2009 1Q FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6) (08/4-6) (09/1-3) (09/4-6) 北米 -1.2
19 528.7 Consolidated: Geographical Segment - Japan Page 19 Net sales Operating income ー FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
20 219.5 Consolidated: Geographical Segment - Europe Page 20 Net sales Operating income FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
21 101.5 Consolidated: Geographical Segment - North America Page 21 Net sales Operating income ー 3.2 ー 4.2 ー 14.8 FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
22 212.3 Consolidated: Geographical Segment - Asia Page Net sales Operating income FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
23 Consolidated: Geographical Segment - Others Page Net sales Operating income ー FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6)
24 Consolidated: Number of Consolidated subsidiaries, Equity method affiliates, Employees Page ,944 51, Consolidated subsidiaries Equity method affiliates Employees FY2008 1Q FY2009 1Q FY2008 1Q FY2009 1Q FY2008 1Q FY2009 1Q (08/6) (09/6) (08/6) (09/6) (08/6) (09/6)
25 Consolidated: Inventory Page 25 Net sales Inventory Overseas inventory included (07/10-12) (08/1-3) (08/4-6) (08/7-9) (08/10-12) (09/1-3) (09/4-6) (298.6) (+73.8) (-13.3) (-100.9) (-194.7) (311.9) (279.7) (255.2) (223.2) (+55.3) (193.3) (-93.0) (184.8) /12 08/3 08/6 08/9 08/12 09/3 09/6
26 Consolidated: FY2009 Forecast (Unchanged from original forecast) Lower earnings on lower sales Page 26 FY2009 Forecast FY2008 Actual Net sales 2, ,004.8 Operating income Ordinary income Net income ForEX rate US dollar 90 yen 101 yen Euro 115 yen 144 yen
27 Production: Motorcycle Page 27 Domestic production Overseas production 3,305 Unit: thousands -12.7% 2, ,993 2, FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6) FY2008 FY2009 Forecast
28 Sales: Motorcycle Page 28 Domestic sales Overseas sales Unit: thousands 991 3, % 3, ,222 2, FY2008 1Q FY2008 4Q FY2009 1Q (08/4-6) (09/1-3) (09/4-6) FY2008 FY2009 Forecast
29 Production: Automobile Page 29 Domestic production Overseas production 2,494 Unit: thousands -7.7% 2, ,355 1,139 1, FY2008 1Q FY2008 4Q FY2009 1Q FY2008 FY2009 (08/4-6) (09/1-3) (09/4-6) Forecast
30 Sales: Automobile Page 30 Domestic sales Overseas sales 2,306 Unit: thousands -5.0% 2, ,641 1, FY2008 1Q FY2008 4Q FY2009 1Q FY2008 FY2009 (08/4-6) (09/1-3) (09/4-6) Forecast
31 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION
32 Caution with respect to Forward-Looking Statements The forward-looking statements of this fiscal year mentioned in this document are calculated based on currently available information and assumptions and contain risks and uncertainty. Please note that the actual results may greatly vary by the changes of various factors. Those factors, which may influence the actual results, include economic conditions and the trend of demand in major markets and the fluctuation of foreign exchange rate. (mainly Yen /US dollar rate, Yen/Euro rate). This document is an English translation of the original Japanese document. If there are any discrepancies between this document and the original Japanese document, the original Japanese document prevails.
Consolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationBusiness Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.
Business Results for the First Quarter of FY216/3 August 4, 215 (Tue.) NH Foods Ltd. Contents Contents I. Consolidated Business Results for FY216/3 1Q (Apr. Jun.) II. Outlook for FY216/3 III. Consolidated
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationFiscal Year 2003 Consolidated 1 st Quarter Business Performance. Eisai Co., Ltd.
Fiscal Year 2003 Consolidated 1 st Quarter Business Performance Eisai Co., Ltd. 1 Consolidated 1 st Quarter Performance Net Sales A Start According to Plan 2002 st Quarter 1 st 115.2 2003 st Quarter 1
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationWelcome to LG Electronics
Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationAPPLIANCE TELECOMMUNICATIONS
May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationResults Briefing Junichi Yoshii President & Representative Director
Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income
More information2nd Quarter Financial Analyst Meeting
Fiscal Year Ending March 2017 (145th Business Year) 2nd Quarter Financial Analyst Meeting November 21, 2016 Contents of Today s Presentation 本日のご説明内容 Summary of 2nd Quarter Consolidated Business Performance
More informationJT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007
Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period
More informationBoiron Group confirms its forecasts for year 2008 : sales increase and growth in current operating income.
2008 FIRST QUARTER ACTIVITY IFRS - In thousands of Euros 2007 2007 2008 constant France (1) 0,000 66,087 65,728-0.5% -0.5% Europe excluding France 0,000 33,221 41,346 +24.5% +23.2% North America 0,000
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More information2nd Quarter Financial Analyst Meeting
Fiscal Year Ending March 2016 (144th Business Year) 2nd Quarter Financial Analyst Meeting November 25, 2015 Contents of Today s Presentation 本日のご説明内容 Summary of 2nd Quarter Consolidated Business Performance
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More information2nd Quarter Financial Analyst Meeting
Fiscal Year Ending March 2018 (146th Business Year) 2nd Quarter Financial Analyst Meeting November 22, 2017 Contents of Today s Presentation 本日のご説明内容 Summary of 2nd Quarter Consolidated Business Performance
More informationFirst Half Fiscal Year 2004 Financial Results. Eisai Co., Ltd.
1 First Half Fiscal Year 2004 Financial Eisai Co., Ltd. Consolidated Performance for First Half FY 2004 (billions of yen, %) 2 FY2003 1H FY2004 1H % % Change Net Sales 247.8 100.0 106 261.0 100.0 105 13.2
More informationEnhancing Corporate Value
Goldman Sachs Twenty Sixth Annual Healthcare Conference Enhancing Corporate Value Eisai Co., Ltd. June 15, 2005 Please refer to the US Roadshow, June 2005 material in our WEB site for further information
More informationReview of Half Year 2010
Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming
More informationEisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Eisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Execution of Comprehensive Strategic Collaboration for Eisai s In-house Discovered Anticancer Agent LENVIMA Eisai Conference for Media and
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationEconomic Data LG Innotek Sustainability Report. Sales by Business Unit. Sales by Region. Optics Solution BU 2,980,322
Economic Data Sales by Business Unit Optics Solution BU 2,980,322 Substrate & Material BU Automotive Components & Electronics BU 987,558 1,391,512 LED BU 778,737 Total: 6,138,129 Optics Solution BU 2,745,972
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 4, 2005 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2005
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 6, 2006 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2006
More informationASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012
ASL MARINE DBS Vickers Pulse of Asia Roadshow 10 January 2012 Presentation Outline Group Overview 1Q FY2012 Financial Review (3 months ended 30 September 2011) Operations Review - Shipbuilding - Shiprepair
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationEfforts start to pay off in the fourth quarter
2014 annual sales (1 st January to 31 December 2014) Efforts start to pay off in the fourth quarter Double-digit growth for Food & Beverage in the US (excluding scope effect) Double-digit growth in emerging
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationThromboGenics Business Update H1 2018
Press release 6 September 2018 Regulated Information ThromboGenics Business Update H1 2018 Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder approval for company name change to Oxurion
More informationJT Group Consolidated Financial Results 2018 First Quarter Results
JT Group Consolidated Financial Results 2018 First Quarter Results Naohiro Minami JT Group Chief Financial Officer *Please be reminded that the figures shown on these slides may differ from those shown
More informationDainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
More informationValneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017
Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationThird Quarter Consolidated Financial Results
Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2014 1. Overview of consolidated results 2. Highlights of Business Performance 3. Actual and Forecast of Main Subsidiary
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More information2014 Full Year Results Presentation. Year ended 31 March 2014
2014 Full Year Results Presentation Year ended 31 March 2014 26-30 May 2014 1 Full year result highlights 12 months to 31 March 2014 NZ$M PCP CC 1 Record net profit after tax 97.1 +26% +46% Record operating
More informationREATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationInterim Financial Report First Half results 2011
Regulated information This report is made in order to comply with the Belgian Royal Decree of 14 November 2007. ThromboGenics published its Interim Financial Report in Dutch. ThromboGenics has also produced
More informationFujisawa Announce Financial Results for 1 st Quarter of FY 03/2005
July 30, 2004 Fujisawa Announce Financial Results for 1 st Quarter of FY 03/2005 Japan, July 30, 2004 Fujisawa Pharmaceutical Co., Ltd. today announced its financial results for the first quarter of fiscal
More informationInflation projection of the National Bank of Poland based on the NECMOD model
Warsaw, July 1 Inflation projection of the National Bank of Poland based on the NECMOD model Economic Institute THE JUNE AS COMPARED TO THE FEBRUARY Change in the projection scenario Re-estimation of the
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationWoongjin Coway. 1Q 12 IR Presentation
Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationOverview of consolidated results Main Product Sales Update Development pipelines. KYORIN Holdings, Inc.
First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2012 Overview of consolidated results Main Product Sales Update Development pipelines Reference Segment information for
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationAnnual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationMANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
More informationPassion for progress, care for people
Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationFY 2017 (Ended March 31, 2018) Full Year Financial Results. Reference Data. May 15, Eisai Co., Ltd.
Securities Code: 4523 FY 2017 (Ended 2018) Full Year Financial Results Reference Data May 15, 2018 Eisai Co., Ltd. For Inquiries: Public Relations: TEL +81-(0)3-3817-5120 Investor Relations: TEL +81-(0)3-3817-3016
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationFull Year Update FY2011 May 2011
Full Year Update FY2011 May 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High level
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More informationBoehringer Ingelheim and investment in R&D. Volker Barkmann
Boehringer Ingelheim and investment in R&D Volker Barkmann I. Our Corporation Boehringer Ingelheim in brief Boehringer Ingelheim Center Our headquarters in Ingelheim, Germany Family-owned global corporation
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More information1 st Quarter of Fiscal 2015 Financial Results Conference Call. August 3, 2015
1 st Quarter of Fiscal 2015 Financial Results Conference Call August 3, 2015 1 SGS2020 Rolling Plan (Targets for FY2017) Our vision: Grow as a drug discovery-based pharmaceutical company FY2015 FY2016
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationFisher & Paykel Healthcare
Fisher & Paykel Healthcare Deutsche Bank / Craigs New Zealand Corporate Day 1 Sydney March 2014 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More information